To include your compound in the COVID-19 Resource Center, submit it here.

Pyridorin pyridoxamine: Phase IIb data

The double-blind, U.S. Phase IIb PYR-210 trial in 307 evaluable patients showed that twice-daily 150 and 300 mg Pyridorin each missed the primary endpoint of significantly reducing the progressive increase in serum

Read the full 320 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE